Compare Cassava Sciences Inc (FLNA) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Twilio Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Twilio Inc trades at $211.86 (market cap $32.11B). The key difference: Twilio Inc is far larger — about 604.3× Cassava Sciences Inc's market cap, and Twilio Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | TWLO | |
|---|---|---|
Market Cap | $53.14M | $32.11B |
Sector | Health | Technology |
52-Week High | $4.64 | $236.64 |
52-Week Low | $1.09 | $92.44 |
Enterprise Value | -$33.43M | $30.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Twilio (TWLO) trades at $217.83, showing modest daily weakness (-0.19%) but maintaining strong momentum with three consecutive earnings beats. The stock exhibits bullish technical signals with positive moving averages and strong institutional support. Recent financials show a significant turnaround with revenue reaching $5.07B in 2025 and net income turning positive at $33.83M, marking the company's first profitable year after previous losses. CEO Khozema Shipchandler's turnaround strategy and AI integration are driving renewed investor confidence.
Twilio presents a compelling turnaround story with improving fundamentals and strong analyst support (76.9% buy ratings), though elevated valuations (P/E 320.52) warrant caution. The company's AI-powered communication platform growth and margin expansion potential support upside to the $215.14 consensus target. Key risks include competitive pressures in customer engagement software and the need to sustain recent profitability gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
